|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Baxter Healthcare Corporation |
| Information provided by: | Baxter Healthcare Corporation |
| ClinicalTrials.gov Identifier: | NCT00161954 |
Purpose
The objective of this study is to establish the earliest time point at which vaccines are expected to show seropositive antibody levels after vaccination with FSME-IMMUN 0.5 mL using a rapid immunization schedule (2 vaccinations administered 12 +/- 2 days apart.
| Condition | Intervention | Phase |
|
Encephalitis, Tick-Borne |
Biological: Tick-Borne Encephalitis (TBE) Vaccine (Inactivated) |
Phase IV |
| MedlinePlus related topics: | Childhood Immunization Encephalitis |
| Study Type: | Interventional |
| Study Design: | Prevention, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment |
| Official Title: | Open Phase IV Clinical Study to Evaluate the Immunogenicity and Safety of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years |
Eligibility
| Ages Eligible for Study: | 16 Years to 65 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Belgium | |||||
| SGS Biopharma Research Unit Stuivenberg | |||||
| Antwerp, Belgium, 2060 | |||||
| Baxter Healthcare Corporation |
| Principal Investigator: | Baxter BioScience Investigator | Baxter BioScience |
More Information
| Study ID Numbers: | 225 |
| First Received: | September 8, 2005 |
| Last Updated: | October 19, 2006 |
| ClinicalTrials.gov Identifier: | NCT00161954 |
| Health Authority: | Belgium: Directorate general for the protection of Public health: Medicines |
|
|
|
|
|